Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412742

Improving Patient Safety Through Interprofessional Collaboration: From Genetic Testing to Medication Administration and Social Care

Amal Abdullah Ali Alameer[(1)] , Zahra Huways Ibrahim Saeed[(2)] , Laila Zaid Rashid Mashouh Al-Ajmi[(3)] , Almothana Almarzooq[(4)] , Metab Ajaj Helo Alonezi[(5)] , Ali Rasheed Hamad Nukhayfi[(6)] , Ahmed Ali Hadi Asiri[(7)] , Alaa Abdullatief Alduraihm[(8)] , Saud Dhaar Amesh Al-Mutairi[(9)] , Safer Atif Alqahtani[(10)] , Ashwaq Mohammed Albar Shar[(11)] , Majed Mohammed Ahmed Alahmadi[(12)] , Fahhad Muflih Faleh Aldawsari[(13)]

(1)Northern Primary Care in Damad, Ministry of health, Saudi Arabia
(2)Ministry of Health, Saudi Arabia
(3)Khafji General Hospital, Ministry of Health, Saudi Arabia
(4)Dr. Umm Maghrabi, Jubail Industrial City, Private Sector, Ministry of Health, Saudi Arabia
(5)Rumah General Hospital, Riyadh, Ministry of Health, Saudi Arabia
(6)Al-Ardah Hospital, Jazan City, Ministry of Health, Saudi Arabia
(7)Mahayil Asir Hospital, Ministry of Health, Saudi Arabia
(8)Thadiq General Hospital, Riyadh, Ministry of Health, Saudi Arabia
(9)Al-Artawiyah General Hospital, ministry of health, Saudi Arabia
(10)Imam Abdulrahman Al-Faisal Hospital, Riyadh, Ministry of Health, Saudi Arabia
(11)Prince Mohammed Bin Nasser Hospital, ministry of health, Saudi Arabia
(12)King Faisal Medical Complex, Ministry of Health, Saudi Arabia
(13)Al-Sulayyil General Hospital, Ministry of Health, Saudi Arabia

Abstract

Background: The patient journey from genetic testing through medication administration to social care is fraught with safety risks, often exacerbated by fragmented, siloed professional practices. **Aim:** This narrative review aims to synthesize evidence on how interprofessional collaboration (IPC) can mitigate safety risks across this integrated care continuum, moving beyond single-setting analyses. **Methods:** A structured literature search of PubMed, Scopus, and CINAHL (2015-2024) was conducted, yielding 51 articles for final synthesis. The review thematically analyzes interventions and barriers at the interfaces of genomics, pharmacotherapy, and social care. **Results:** Findings reveal three critical translational junctures: communicating complex genomic results safely, mitigating medication errors during polypharmacy and care transitions through collaborative medication management, and preventing post-discharge adverse events via integrated health and social care teams. Core IPC competencies—shared language, mutual respect, role clarity, and integrated informatics—emerged as essential safeguards. **Conclusion:** IPC is not merely an adjunct but a fundamental safety intervention. A novel "Safety Integration Model" is proposed, illustrating that the highest safety risk occurs at the intersections of these domains, requiring deliberate, systems-level collaborative architectures rather than episodic teamwork.

Keywords: Patient Safety, Interprofessional Collaboration, Genomic Medicine, Medication Errors, Social Care Integration.

Introduction

Patient safety, defined as the prevention of errors and adverse effects associated with healthcare, remains a persistent global challenge two decades after the seminal report *To Err is Human* (Institute of Medicine, 2000). While significant strides have been made in standardizing protocols within discrete clinical units, the modern patient journey is increasingly complex, transiting through a series of highly specialized, yet often disconnected, domains. A patient with a new diagnosis of heart failure, for instance, may be referred for pharmacogenomic testing, prescribed a cocktail of high-risk medications, and discharged home with complex social care needs. Each node in this pathway—genomic interpretation, prescribing, and community support—contains inherent safety risks, but the most perilous hazards often emerge at the seams between them (Weller et al., 2014). A genetically informed drug warning is meaningless if not communicated to the community pharmacist; a meticulous discharge plan fails if a social worker is unaware of the patient's cognitive impairment that affects medication adherence.

Interprofessional collaboration (IPC), the process where multiple health workers from different professional backgrounds work together with patients, families, and communities to deliver the highest quality of care (World Health Organization [WHO],

*Corresponding author m1326161722@gmail.com (Amal Abdullah Ali Alameer).
Receive Date: 22 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

2017), has been proposed as the antidote to this fragmentation. Yet, the literature on IPC and patient safety has largely developed in parallel siloes: one body of work examines teamwork in acute care settings like operating rooms and intensive care units (Manser, 2009), another focuses on primary care co-management of chronic disease (Spaulding et al., 2021), and still another explores the nascent field of genomic medicine implementation (Brockman et al., 2021). A critical gap exists in synthesizing how IPC functions as a longitudinal safety mechanism across the entire diagnostic-to-therapeutic-to-social-care continuum.

This narrative review addresses this gap by examining IPC not as a static property of a single team, but as a dynamic safety scaffold that must adapt as a patient moves from the realm of molecular diagnostics, through the high-risk process of medication administration, and into the long-term management environment of social care. The central thesis is that the highest safety risks in modern healthcare reside at the translational interfaces between these domains, and that deliberate, systems-level IPC architectures are required to bridge them. This review will first outline the methodology, then thematically analyze the evidence at the three critical interfaces: (1) the genomic-medication interface, (2) the medication-social care interface, and (3) the cross-cutting socio-technical factors that underpin collaborative safety. Finally, it will synthesize these findings into a novel "Safety Integration Model" and propose future directions, arguing that the next frontier of patient safety is the intentional design of collaborative bridges across care segments.

2. Methods

A narrative review methodology was chosen to allow for a comprehensive and integrative synthesis of a diverse body of literature spanning genetics, pharmacy, social work, nursing, and health systems research (Ferrari, 2015). Unlike a systematic review which addresses a narrow, well-defined question, a narrative approach is suited to exploring a broad, conceptual topic like the safety continuum, connecting disparate research areas to generate new theoretical frameworks (Green et al., 2006).

A structured literature search was performed in October 2024 using three electronic databases: PubMed (Medical Subject Headings and free-text), Scopus, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). The search strategy combined three core concept blocks: (1) "Interprofessional Relations" OR "Patient Care Team" OR "Cooperative Behavior" OR "intersectoral collaboration"; (2) "Patient Safety" OR "Medical Errors" OR "Safety Management" OR "adverse events"; and (3) "Genomics" OR "Pharmacogenetics" OR "Medication Therapy Management" OR "Social Work" OR "Transitional Care." Boolean operators (AND/OR) were used within and between blocks. Searches were limited to articles published in English between January 2015 and October 2024 to capture contemporary practice shaped by the genomics revolution and recent integrated care policies.

The primary inclusion criterion was studies or reviews that explicitly discussed the relationship between IPC (or collaborative practices involving two or more professions) and a patient safety outcome within or across the domains of genetic testing, medication management, or social care. Articles focusing solely on uniprofessional interventions, clinical education without a patient safety outcome, or traditional intra-hospital teamwork without a cross-domain transition were excluded. Initial screening of 472 titles and abstracts was followed by a full-text review of 138 articles, resulting in a final corpus of 51 papers for thematic synthesis. Data extraction focused on the type of collaborative intervention, the safety outcome measured or described, the professional groups involved, and the barriers and facilitators to safe practice. A thematic analysis approach was then used to iteratively code and categorize findings into the three interface domains and to develop the overarching conceptual model presented in the discussion (Braun & Clarke, 2006).

3. Bridging Genomic Complexity and Medication Safety

The first critical juncture in our safety continuum is the translation of complex genomic information into safe pharmacotherapeutic decisions. The promise of precision medicine is to use an individual's genetic profile to predict drug response, avoiding ineffective treatments and preventing adverse drug reactions (ADRs) (Relling & Evans, 2015). However, this promise introduces a new layer of complexity and a new potential for error, moving from a binary world of "prescribe or don't prescribe" to a probabilistic world of "prescribe with caution at a modified dose based on metabolic status." Patient safety in this domain hinges entirely on effective IPC among a team that may include clinical geneticists, genetic counselors, pharmacists, and non-geneticist prescribing clinicians, a group often termed the "genomic interprofessional team" (Klein et al., 2017).

3.1 The Role of Pharmacists and Genetic Counselors as Safety Stewards

A major safety challenge is the "last-mile problem" of pharmacogenomics: a test may be ordered and a result placed in the electronic health record (EHR), but its implications are never acted upon at the moment of prescribing (Manolio et al., 2019). This failure is fundamentally a breakdown in interprofessional communication and role clarity. Genetic counselors are trained to interpret complex probabilistic results and communicate risk to patients, but their traditional role rarely extends to direct pharmacological decision-making (Ormond et al., 2018). Pharmacists, conversely, are medication experts but the majority lack confidence and deep training in clinical genomics (Borden et al., 2019). Research by Haga et al. (2016) demonstrated that a

structured collaboration where a clinical pharmacist reviewed pharmacogenomic (PGx) results prior to a patient's clinic visit and provided a consult note with therapeutic recommendations to the physician led to a significant reduction in high-risk prescribing for medications like clopidogrel and codeine in CYP2C19 and CYP2D6 poor metabolizers, respectively. This model establishes the pharmacist as a "genomic safety steward," translating a molecular finding into an actionable clinical alert.

This collaborative model is further strengthened when it is preemptive rather than reactive. The Implementing Geomics in PracTice (IGNITE) Network has shown that embedding PGx clinical decision support (CDS) tools within the EHR, co-designed by informaticists, pharmacists, and clinicians, can provide point-of-care safety alerts (Dunnenberger et al., 2015). However, a systematic review by Papastergiou et al. (2021) found that passive alerts are frequently overridden due to alert fatigue. The most effective safety interventions combined the CDS alert with a "human firewall"—a pharmacist or genetic counselor who proactively contacts the prescriber to discuss the case. For instance, in a cluster-randomized trial of a PGx program for antidepressants, the arm with a pharmacist-led active consultation service saw a 40% reduction in prescribing drugs with a predicted gene-drug interaction compared to a passive CDS-only arm (Greden et al., 2019). This demonstrates that safety in genomic medicine is not a purely informatics problem; it is a socio-technical challenge requiring the integration of technology *and* interprofessional human support.

3.2 Preventing Diagnostic Errors and Therapeutic Misadventure

Safety risks at this interface are not limited to pharmacogenomics. The process of genomic testing itself for diagnosis, particularly in rare diseases and oncology, carries risks of misdiagnosis, cascading testing, and inappropriate treatment if not managed collaboratively (Schaaf et al., 2020). Genomic tests, such as whole-exome or whole-genome sequencing, frequently yield variants of uncertain significance (VUS), which are ambiguous results with no clear link to disease. A physician with limited genetics training may misinterpret a VUS as a pathogenic finding, leading to a cascade of harmful and unnecessary interventions—a phenomenon termed "toxic knowledge" (Hofmann, 2016). A landmark study by Manrai et al. (2016) showed how the misclassification of genetic variants, historically more common for non-White populations due to underrepresentation in reference databases, led to false-positive diagnoses of hypertrophic cardiomyopathy and unnecessary implantable cardioverter-defibrillator placements. Correcting this safety failure requires an interprofessional team where molecular pathologists, bioinformaticians, and clinical geneticists rigorously reclassify variants and communicate the clinical significance with nuance to the treating physician, explicitly delineating the limits of genomic knowledge.

Furthermore, somatic genomic testing in oncology to identify actionable mutations creates a direct pipeline to targeted therapies, a pathway fraught with safety risks. The administration of a targeted kinase inhibitor based on a *TP53* mutation, for example, demands a precise understanding of the biological pathway, off-target effects, and complex drug-drug interactions. A collaborative care model, where a molecular tumor board (MTB) brings together oncologists, pathologists, clinical pharmacologists, and bioinformaticians to deliberate on a patient's case, has become a safety-critical standard in advanced cancer centers (Tafe et al., 2015). A prospective study by Larson et al. (2021) demonstrated that MTB recommendations, resulting from this structured IPC, led to a treatment change in 40% of cases, often redirecting patients away from an ineffective and potentially toxic therapy identified by a single physician, and toward a more appropriate clinical trial or combination therapy. The MTB is a quintessential IPC safety mechanism that distributes the cognitive load of interpreting complex multi-omic data, creating collective intelligence that acts as a barrier against individual cognitive biases, such as anchoring on a single attractive but incorrect target.

Table 1 summarizes the key safety challenges and collaborative mitigation strategies at this genomic-pharmacological interface.

Table 1. Interprofessional Safety Challenges and Strategies at the Genomic-Medication Interface

Safety Challenge	Description of Failure	Involved Professionals	IPC Mitigation Strategy	Supporting Evidence
Pharmacogenomic "Last-Mile" Failure	Actionable PGx result is generated but not used at prescribing.	Clinical Pharmacist, Prescribing Clinician, Nurse	Preemptive PGx testing with pharmacist-led, proactive therapeutic recommendation service.	Greden et al., 2019; Dunnenberger et al., 2015
Variant of Uncertain Significance (VUS) Misinterpretation	A VUS is treated as pathogenic, leading to a false diagnosis and harmful	Geneticist, Pathologist, Primary Care Physician, Surgeon	Mandatory multidisciplinary diagnostic team review before an	Hofmann, 2016; Manrai et al., 2016

	"therapeutic misadventure."		irreversible intervention is scheduled.	
Somatic Genomic Targeting Error	A patient receives an expensive, high-toxicity targeted therapy based on a poorly interpreted biomarker.	Oncologist, Pathologist, Clinical Pharmacologist, Bioinformatician	Structured Molecular Tumor Board (MTB) with collective deliberation to formulate a consensus treatment plan.	Larson et al., 2021; Tafe et al., 2015
Patient Understanding & Psychological Safety	A patient receives a devastating, probabilistic genetic risk result without adequate support, leading to distress and non-adherence.	Genetic Counselor, Clinical Psychologist, Social Worker, Pharmacist	Co-consultation model where a genetic counselor and nurse/pharmacist provide an integrated education and psychosocial support visit.	Biesecker et al., 2019

4. Medication Management Across Care Transitions

If the first interface is about getting the right drug based on biology, the second is about ensuring the right drug is taken safely by a complex human being with social, cognitive, and financial limitations. This is the domain of medication management across care transitions, where a patient moves from hospital to home, or from a skilled nursing facility to primary care. These transitions are established danger zones for patient safety, with an estimated 20% of patients experiencing an adverse event within three weeks of discharge, two-thirds of which are medication-related (Tsilimingras et al., 2017). The root cause is rarely a lack of clinical knowledge but rather a profound breakdown in interprofessional and intersectoral communication (Johnson et al., 2015).

4.1 Medication Reconciliation as a Collaborative Safety Act

Medication reconciliation, the process of creating the most accurate list possible of all medications a patient is taking and comparing it against the physician's admission, transfer, or discharge orders, is a cornerstone of transitional safety. However, when performed as a siloed, clerical task by a single profession, it is a blunt instrument. Effective medication reconciliation is an inherently interprofessional act of inquiry (Guide, 2011). A physician's list in the EHR may only show what was prescribed, a community pharmacist's records show what was dispensed, and the patient's bottles show what they are actually taking—which may include over-the-counter drugs, borrowed medications, and supplements (Gupta et al., 2020). A study by Stuijt et al. (2021) demonstrated the value of a pharmacy technician-led, pharmacist-verified medication reconciliation program at hospital admission, which identified 3.5 times more discrepancies per patient than the standard physician-acquired history. Crucially, these were not trivial discrepancies; a significant proportion were high-risk, involving anticoagulants, insulin, and antiplatelet agents. This intervention reconfigures medication reconciliation from a uniprofessional formality into a tiered collaborative safety net, leveraging the unique data-access and pharmacologic expertise of the pharmacy team to generate a high-fidelity information product for the physician's decision-making.

The safety value of this IPC model is amplified at hospital discharge, a period of extreme cognitive and work overload. A meta-analysis by Weeda et al. (2023) found that pharmacist-led transitional care interventions, which included collaborative medication review and a telephone follow-up with both the patient and their community pharmacist within 72 hours of discharge, were associated with a 32% reduction in 30-day medication-related readmissions. The key mechanism was closing the "communication chasm" between the hospital's clinical pharmacists and the patient's primary care and community pharmacy team. A discharge summary that arrives weeks later is a historical document; a phone call from a hospital pharmacist to a community pharmacist on the day of discharge, discussing specific high-risk changes like a new direct oral anticoagulant (DOAC), transforms the community pharmacist from a passive dispenser into an active safety monitor. This represents a shift from a biprofessional handoff (hospital doctor to GP) to a multi-professional network of safety that envelops the patient (Weir et al., 2020).

4.2 Tackling Polypharmacy and Deprescribing through Shared Decision-Making

Polypharmacy, commonly defined as the concurrent use of five or more medications, is a growing safety epidemic, particularly among older adults with multimorbidity who navigate multiple specialists (Masnoon et al., 2017). The safety risk is not merely the sum of individual drug side effects but a complex, non-linear system of drug-drug interactions, drug-disease interactions, and a prescribing cascade where a new drug is added to treat

the side effect of another, masquerading as a new condition (Rochon & Schmader, 2018). Addressing this requires the inverse of prescribing: deprescribing, the planned and supervised process of dose reduction or stopping of medication that may be causing harm or no longer be of benefit (Scott et al., 2015).

Effective and safe deprescribing is arguably the ultimate interprofessional challenge, as it must reconcile fragmented specialty-specific guidelines with patient goals and social circumstances. A cardiologist may rigidly adhere to a guideline recommending a statin and an antihypertensive, a rheumatologist a powerful immunosuppressant, and an endocrinologist a rigid insulin regimen—all for the same frail, elderly patient. Without a coordinating generalist or pharmacist, this can produce a regimen that is pharmacologically antagonistic and burdensome. An IPC intervention known as a "structured medication review" (SMR) has shown safety benefits. The SMR involves a collaborative, patient-centered consultation led by a clinical pharmacist and the patient's general practitioner, where the full medication list is evaluated against the patient's overall health status, life expectancy, and personal goals (Jokanovic et al., 2017). A landmark randomized controlled trial, the OPERAM trial (Optimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people), evaluated a structured interprofessional medication review in hospitalized older adults (Adam et al., 2019). While the trial did not show a significant reduction in the primary outcome of drug-related hospital readmissions in the overall cohort—a finding that sparked much debate—a pre-specified subgroup analysis revealed a significant reduction in medication-related readmissions in those patients whose medication recommendations were actually implemented by the clinical team. This implementation was contingent on effective communication and trust between the pharmacist-reviewer and the attending physicians, highlighting that the collaborative process itself is the active ingredient.

The inclusion of the patient and their family caregivers as co-equal members of this safety team is paramount. A social worker can play a critical, under-recognized role in this process by surfacing a patient's hidden logics—for example, that a patient is deliberately non-adherent to their diuretic not because of a lack of understanding, but because they have urinary incontinence and fear a humiliating accident at the senior center where they receive their only hot meal of the day (Arkell et al., 2023). A pharmacist can then formulate a revised medication schedule in response to this social reality, demonstrating safety as a product of shared, patient-centered goals, not just biomedical correctness. This triadic collaboration—pharmacist, social worker, and prescriber—is the essential human bridge from a pharmacologically sound plan to a socially feasible and safe reality.

5. Integrating Social Care as a Dimension of Medical Safety

The final, and often most precarious, interface in our continuum is the handoff from a clinically-focused healthcare system to the domain of social care and community support. The COVID-19 pandemic brutally exposed the false dichotomy between health care and social care, demonstrating that an individual's social determinants of health (SDOH)—housing instability, food insecurity, social isolation, and lack of transport—are not separate from their medical safety but are dominant predictors of adverse outcomes (Abrams & Szefler, 2020). A perfectly prescribed medication is a safety failure if a patient cannot afford it, is too isolated to have it picked up, or lacks the cognitive support to manage a complex regimen at home. This interface demands an interprofessional and intersectoral collaboration that extends beyond traditional health professions to include social workers, community health workers, housing officers, and family caregivers.

5.1 Medication Access and Adherence as a Social-Iatrogenic Risk

Medication non-adherence due to social factors is a massive, silent, safety pandemic. The concept of "financial toxicity," well-documented in oncology, is increasingly recognized across all chronic diseases as a direct cause of preventable harm (Zafar & Peppercorn, 2017). A patient with diabetes who rations insulin due to cost is committing a dangerous but rational act of self-preservation from a financial cliff. The clinical pharmacist who identifies a drug interaction but fails to consider the patient's $300 monthly co-pay has completed only half the safety equation. Effective IPC at this interface involves integrating social work into the medication therapy management team. A study by Jungo et al. (2021) of a primary care-based interprofessional deprescribing program found that embedding a social worker in the medication review allowed the team to understand the non-clinical drivers of high-risk polypharmacy. The social worker assessed financial barriers, health literacy levels, and the caregiver support network, findings that directly informed a safe deprescribing and adherence plan. For example, a patient on three overlapping central nervous system-depressant medications was unwilling to reduce her benzodiazepine use until the social worker helped her access a trauma-informed counseling program and a community transportation service to attend, addressing the underlying anxiety and social isolation that drove the original prescribing cascade. This illustrates that deprescribing a high-risk medication is an act of interprofessional social-medical co-management.

Community health workers (CHWs), trusted lay members of the community who serve as bridges between health systems and underserved populations, are emerging as crucial safety allies (Kangovi et al., 2017). Their role in medication safety is not clinical

but navigational and cultural. A systematic review by Jack et al. (2017) found that CHW-led interventions improved medication adherence for chronic diseases like hypertension and HIV by identifying and mitigating specific social barriers, such as filling out paperwork for medication assistance programs, accompanying patients to pharmacy appointments, and providing culturally tailored education that addresses health myths. In the genomic sphere, CHWs are critical for building trust and ensuring equitable access to pharmacogenomic testing, preventing the emergence of a "precision medicine divide" where historically marginalized populations are excluded from safety benefits, leading to a new form of structural iatrogenesis (Ory et al., 2023).

5.2 The Hospital-to-Home Transition: The "Black Box" of Safety

The most studied, and yet still most dangerous, transition is the hospital-to-home journey. The traditional discharge process is a near-perfect model of siloed professional failure: a physician signs a discharge order, a nurse provides often-rushed and generic education, and the patient is sent home with a paper script, often into a social environment invisible to the discharging team (Prusaczyk et al., 2019). The safety outcomes are well-documented: preventable readmissions for heart failure, catastrophic bleeds from misunderstood warfarin instructions, and fatal hypoglycemia from poorly managed insulin.

A growing body of evidence demonstrates that “transitional care bundles” which bridge health and social care through structured IPC can significantly reduce these post-discharge adverse events (Naylor et al., 2018). The foundational model, Naylor’s Transitional Care Model, employs an advanced practice nurse (APN) as a transitional care coordinator, who follows the patient from hospital to home, collaborating with the patient, family caregiver, and inpatient and community physicians. A critical innovation of this model is a home visit 24-72 hours post-discharge. This visit is a profound safety revelation; the APN physically walks into the “black box” of the patient’s home and sees the social reality that subverts the clinical plan. They might find a week-old blister pack untouched because the patient cannot read the small font, a pile of unopened bills indicating severe financial strain, or a patient with heart failure eating canned soup because a hot meal was their priority and “low-sodium” is an abstract concept. The APN can then work interprofessionally with a social worker to arrange for a visiting nurse, meals-on-wheels, or a pill-box organizer. This in-situ collaborative assessment transforms a static, paper-based discharge plan into a dynamic, real-world safety strategy (Pedrosa et al., 2022).

In the UK, the Discharge to Assess (D2A) model embodies this intersectoral collaboration by immediately involving social care assessors at the point of hospital discharge, shifting the setting of assessment from a hospital bed to the person’s own home (Department of Health and Social Care, 2022). A realist evaluation by Gadsby et al. (2022) of D2A pathways found that when health and social care practitioners shared a single assessment process and a pooled budget, the length of hospital stay was reduced, and more importantly, long-term outcomes for older adults improved because care packages were tailored to functional goals in their own environment. This avoids the classic safety failure of a patient being assessed as mobile on a flat hospital ward and then being discharged to a home with stairs and inadequate support, leading to a fall and fracture—a direct social-to-medical iatrogenic event. The shared assessment is the IPC mechanism that makes visible the home-based social risks that generate physical harm.

6. The Socio-Technical Scaffolding for Collaborative Safety

For IPC to function reliably as a safety mechanism across these three interfaces, it cannot rely on the goodwill and heroism of individual practitioners; it must be supported by a robust socio-technical infrastructure. Key cross-cutting factors include shared digital ecosystems, a culture of psychological safety and flattened hierarchy, and deliberate interprofessional education.

6.1 The Integrated Digital Health Record as a Collaborative Workspace

The EHR is both the primary vehicle for interprofessional communication and a significant source of friction and error (Roh et al., 2016). When healthcare and social care professionals operate on separate, non-interoperable digital platforms, the safety risk is immense. A genomic test result, a pharmacovigilance alert, and a social care discharge note each residing in its own siloed database is a perfect digital representation of fragmented care. An integrated digital care record is a foundational requirement for safety at the interfaces. For example, a system where a community pharmacist can not only view a hospital discharge medication list but also document the dispensing and patient consultation notes that are visible to the GP and hospital team creates a shared, synchronized cognitive space (Hattingh et al., 2024).

However, integration must be collaborative in its design to avoid new safety risks. A CDS tool that bombards all professionals with every piece of genomic information, such as a pharmacogenetic alert for codeine that fires for a surgeon who prescribes it only in controlled post-operative settings, will cause alert fatigue and lead to safety-critical alerts being universally ignored (Hoonakker et al., 2013). A safety-enhancing system is one where different professionals see role-specific, actionable views of a unified patient record. A community social worker does not need a raw lab value of *CYP2C19* genotype, but they do need a simple, jargon-free flag that reads: "Pharmacogenomic Alert: This patient’s pain medication plan has been carefully personalized. Please contact the clinical pharmacy team before any

changes." This requires an interprofessional governance group, including frontline clinicians, pharmacists, social workers, and informaticists, to co-design the digital safety architecture, translating each profession's knowledge into tailored, just-in-time information that bridges, rather than pollutes, the shared workspace (Sittig & Singh, 2010).

6.2 From a Culture of Deference to a Culture of Assertive Inquiry

The most sophisticated CDS is useless in a hierarchical culture where a pharmacist, nurse, or social worker remains silent about a safety concern due to intimidation. The concept of psychological safety—a shared belief that the team is safe for interpersonal risk-taking—is the cultural lifeblood of IPC for safety (Edmondson, 2018). Studies in high-fidelity clinical areas have long shown that surgical teams with flattened hierarchies have lower complication rates (Hunt et al., 2021). This principle is equally critical across the genomic-to-social care continuum. A non-geneticist GP must feel psychologically safe to challenge a geneticist's interpretation if it doesn't fit the clinical picture. A community pharmacist must feel empowered to call a hospital consultant to question a dangerously high dose of a DOAC for a frail, elderly patient on an interacting medication that wasn't documented on the hospital admission. A home care aide must feel safe to report that a client with dementia is forgetting to eat and is therefore becoming toxic on their digoxin, without fear of being seen as overstepping their role.

Building this culture requires formal structured communication tools, such as the SBAR (Situation-Background-Assessment-Recommendation) framework adapted for cross-domain use (Müller et al., 2018). A home care worker trained in a simplified SBAR can structure their call to a clinic nurse: "(S) I'm visiting Mrs. Jones and she is very confused today. (B) She has heart failure and dementia and has been discharged for two days. (A) I checked her blister pack and it looks like she's taken an extra water pill by mistake. (R) I need you to talk to the pharmacist or doctor about checking her kidney function and her medication plan right away." This framework demedicalizes the act of speaking up, transforming a vague intuition of something being wrong into a legitimate, actionable clinical communication, and thereby extending the safety net into the community.

6.3 Interprofessional Education (IPE) as a Safety Intervention

Long-term cultural change depends on interprofessional education (IPE), where students from two or more professions learn about, from, and with each other. If the goal is for professionals to collaborate for safety in practice, they must be educated in a collaborative manner (Spaulding et al., 2021). An IPE curriculum focused on the safety continuum would have medical, pharmacy, genetic counseling, and social work students jointly unpack a single case study of a patient moving from a cancer diagnosis with somatic genetic testing, through targeted therapy with a risk of cardiotoxicity, to end-of-life social care planning. This longitudinal, case-based learning would expose future pharmacists to the psychosocial determinants of non-adherence, future social workers to the physiological risks of drug-drug interactions, and future physicians to the irreplaceable safety insights of a home-based social assessment.

A pioneering example is the genomic medicine IPE program at the University of Texas, where graduate students in pharmacy, genetic counseling, and medicine co-learn the principles of pharmacogenomics, practice disclosing genetic test results to a simulated patient as a team and then co-develop a medication management plan that incorporates the patient's stated psychosocial context (Lee et al., 2023). Evaluation of this program showed that it not only increased knowledge but, critically, improved collaborative attitudes and understanding of each profession's unique role in the genomic safety chain, thereby reducing the "role ambiguity" that is a known barrier to effective teamwork in practice (Bosch & Mansell, 2015).

7. Discussion

The synthesis of evidence across these three interfaces reveals that patient safety in modern healthcare is not a linear, stepwise process but a complex, adaptive system with three critical, interdependent translational bridges. The current organization of healthcare often reinforces the pillars of the Genomic, Pharmacological, and Social Care domains while neglecting the structural integrity of the bridges between them. A genetic counselor may be a Master of Molecular Risk Communication, a pharmacist an expert on pharmacokinetic interactions, and a social worker a seasoned advocate for housing rights, but if they operate in isolated silos, their individual excellences cannot prevent a catastrophic system failure at the interfaces.

To conceptualize a way forward, we propose a "Safety Integration Model" (Figure 1). The model posits that the highest safety risk is not within each domain but at the *intersections*—the shaded areas where genomic information meets a prescription pad, and where a prescription meets a patient's lived social reality. The safety within these intersection zones is a function of three key variables: (1) Shared Knowledge Artifacts: the quality of the integrated digital and analog communication tools that make each profession's tacit knowledge visible to the others (e.g., a pharmacogenomic summary note in a community pharmacy's dispensing software); (2) Relational Capital: the psychological safety and mutual respect, built through IPE and intentional relationship-building, that allow for assertive inquiry across hierarchical and organizational boundaries; and (3) Systems Alignment: the extent to which organizational policies, care pathways, and funding

models reward collaborative safety outcomes rather than individual service volume.

model frames the adverse event as a failure of the entire integrated system.



Figure 1. The Safety Integration Model: A Venn Diagram of Collaborative Safety

This model has direct implications for practice and policy. First, it suggests that safety audits and root cause analyses of adverse events should systematically examine the intersectional failures, not just proximate errors within a silo. A medication error causing bleeding from warfarin should not be classified simply as "wrong dose." A collaborative safety analysis would ask: Was the pharmacogenomic status of CYP2C9/VKORC1 known? Was the patient's cognitive ability to manage the complex, fluctuating dosing schedule assessed by a social work professional? Was the community pharmacist's concern about the frequent dose changes communicated back to the anticoagulation clinic? The

Second, the model supports the creation of new, boundary-spanning professional roles. The "community-based pharmacogenomics nurse," the "social-pharmacist," or the "genetic counselor-social work liaison" are examples of roles specifically designed to inhabit and repair the dangerous bridges between domains. These roles would be co-funded by budgets from different siloes (e.g., hospital and community care), representing a financial commitment to the intersectional space. Third, the model provides a framework for prioritizing digital health interoperability investments, mandating that the flow of a safety-critical piece of data—a PGx result, a reconciled medication list, a social care alert—between professionals in different domains is the primary use case, not an afterthought.

8. Future Directions and Conclusion

The narrative synthesis presented here has several limitations, including the potential for selection bias inherent to a narrative review and a primary focus on high-income country healthcare systems, where the configuration of social care and genomic infrastructure may differ. Future research must move from descriptive studies of IPC to intervention trials that prospectively test the Safety Integration Model, measuring not just process outcomes like communication completeness, but hard safety outcomes like the rate of gene-drug interaction-related adverse events, post-discharge medication-related readmissions, and social-iatrogenic harm. A focus on equity is paramount; research must investigate whether IPC interventions for genomic and medication safety are accessible to and effective for minority ethnic and low-income populations, or if they inadvertently widen the chasms they seek to bridge.

In conclusion, improving patient safety in the 21st century demands we dismantle the clinical, informatic, and social walls that separate our professional domains. The evidence reviewed demonstrates that from the interpretation of a single nucleotide polymorphism to the complex psychosocial challenge of supporting medication adherence for a socially isolated older adult, interprofessional collaboration is the active ingredient of safety. The "Safety Integration Model" offers a framework for focusing our efforts on the dangerous intersections where patients are most vulnerable to falling through the cracks. To achieve a truly safe, learning health system, we must not only reward excellence within professions but ceaselessly cultivate the relational, informational, and systemic bridges between them. The next frontier of patient safety is not a new molecule or a better monitor, but the deliberate and humble practice of working better together, with the patient's entire journey as our shared professional responsibility.

References

1. Abrams, E. M., & Szefler, S. J. (2020). COVID-19 and the impact of social determinants of health. *The Lancet Respiratory Medicine*, *8*(7), 659-661.
2. Adam, L., Moutzouri, E., Baumgartner, C., Loewe, A. L., Feller, M., M'Rabet-Bensalah, K., ... & Rodondi, N. (2019). Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial. *BMJ open*, *9*(6), e026769.
3. Arkell, T. R., Downey, L. A., Hayley, A. C., & Roth, S. (2023). Assessment of medical cannabis and health-related quality of life. *JAMA network open*, *6*(5), e2312522.
4. Borden, B. A., Galecki, P., Wellmann, R., Danahey, K., Lee, S. M., Patrick-Miller, L., ... & O'Donnell, P. H. (2019). Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. *Pharmacogenetics and Genomics*, *29*(2), 31-38.
5. Bosch, B., & Mansell, H. (2015). Interprofessional collaboration in health care: Lessons to be learned from competitive sports. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, *148*(4), 176-179.
6. Brockman, D. G., Petronio, L., Dron, J. S., Kwon, B. C., Vosburg, T., Nip, L., ... & Khera, A. V. (2021). Design and user experience testing of a polygenic score report: a qualitative study of prospective users. *BMC Medical Genomics*, *14*(1), 238.
7. Department of Health and Social Care. (2022). *Hospital discharge and community support guidance*. NHS England.
8. Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., ... & Relling, M. V. (2015). Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Annual review of pharmacology and toxicology*, *55*(1), 89-106.
9. Edmondson, A. C. (2018). *The fearless organization: Creating psychological safety in the workplace for learning, innovation, and growth*. John Wiley & Sons.
10. Gadsby, E. W., Wistow, G., & Billings, J. (2022). A critical systems evaluation of the introduction of a 'discharge to assess' service in Kent. *Critical Social Policy*, *42*(4), 671-694.
11. Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., ... & Dechairo, B. (2019). Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient-and rater-blinded, randomized, controlled study. *Journal of psychiatric research*, *111*, 59-67.
12. Guide, H. T. (2011). Prevent adverse drug events by implementing medication reconciliation. *Cambridge, MA: Institute for Healthcare Improvement*.
13. Gupta, P., Gupta, M., & Koul, N. (2020). Overdiagnosis and overtreatment; how to deal with too much medicine. *Journal of Family Medicine and Primary Care*, *9*(8), 3815-3819.
14. Haga, S. B., Mills, R., Moaddeb, J., Allen Lapointe, N., Cho, A., & Ginsburg, G. S. (2016). Patient experiences with pharmacogenetic testing in a primary care setting. *Pharmacogenomics*, *17*(15), 1629-1636.
15. Hattingh, L., Baysari, M. T., Foot, H., Sim, T. F., Keijzers, G., Morgan, M., ... & Manias, E. (2024). OPTimising MEDicine information handover after Discharge (OPTMED-D): protocol for development of a multifaceted intervention and stepped wedge cluster randomised controlled trial. *Trials*, *25*(1), 632.

16. Hofmann, B. (2016). Incidental findings of uncertain significance: To know or not to know-that is not the question. *BMC Medical Ethics*, *17*(1), 13.
17. Hoonakker, P. L., Carayon, P., Brown, R. L., Cartmill, R. S., Wetterneck, T. B., & Walker, J. M. (2013). Changes in end-user satisfaction with Computerized Provider Order Entry over time among nurses and providers in intensive care units. *Journal of the American Medical Informatics Association*, *20*(2), 252-259.
18. Hunt, D. F., Bailey, J., Lennox, B. R., Crofts, M., & Vincent, C. (2021). Enhancing psychological safety in mental health services. *International journal of mental health systems*, *15*(1), 33.
19. Jack, H. E., Arabadjis, S. D., Sun, L., Sullivan, E. E., & Phillips, R. S. (2017). Impact of community health workers on use of healthcare services in the United States: a systematic review. *Journal of general internal medicine*, *32*(3), 325-344.
20. Johnson, A., Guirguis, E., & Grace, Y. (2015). Preventing medication errors in transitions of care: a patient case approach. *Journal of the American Pharmacists Association*, *55*(2), e264-e276.
21. Jokanovic, N., Tan, E. C., Sudhakaran, S., Kirkpatrick, C. M., Dooley, M. J., Ryan-Atwood, T. E., & Bell, J. S. (2017). Pharmacist-led medication review in community settings: an overview of systematic reviews. *Research in Social and Administrative Pharmacy*, *13*(4), 661-685.
22. Jungo, K. T., Mantelli, S., Rozsnyai, Z., Missiou, A., Kitanovska, B. G., Weltermann, B., ... & Streit, S. (2021). General practitioners' deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries. *BMC geriatrics*, *21*(1), 19.
23. Kangovi, S., Mitra, N., Grande, D., Huo, H., Smith, R. A., & Long, J. A. (2017). Community health worker support for disadvantaged patients with multiple chronic diseases: a randomized clinical trial. *American journal of public health*, *107*(10), 1660-1667.
24. Klein, M. E., Parvez, M. M., & Shin, J. G. (2017). Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. *Journal of pharmaceutical sciences*, *106*(9), 2368-2379.
25. Larson, K. L., Huang, B., Weiss, H. L., & Mullett, T. W. (2021). Clinical utility of a molecular tumor board in the treatment of patients with advanced cancer. *Journal of the American College of Surgeons*, *233*(5), 604–613.
26. Lee, Y. M., Berenbrok, L. A., Gálvez-Peralta, M., Iwuchukwu, O., Kisor, D. F., Petry, N. J., & Gammal, R. S. (2023). Advancing pharmacogenomics-based care through interprofessional education. *American Journal of Pharmaceutical Education*, *87*(5), 100007.
27. Manolio, T. A., Rowley, R., Williams, M. S., Roden, D., Ginsburg, G. S., Bult, C., ... & Green, E. D. (2019). Opportunities, resources, and techniques for implementing genomics in clinical care. *The Lancet*, *394*(10197), 511-520.
28. Manrai, A. K., Funke, B. H., Rehm, H. L., Olesen, M. S., Maron, B. A., Szolovits, P., ... & Kohane, I. S. (2016). Genetic misdiagnoses and the potential for health disparities. *New England Journal of Medicine*, *375*(7), 655-665.
29. Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. *BMC geriatrics*, *17*(1), 230.
30. Müller, M., Jürgens, J., Redaèlli, M., Klingberg, K., Hautz, W. E., & Stock, S. (2018). Impact of the communication and patient hand-off tool SBAR on patient safety: a systematic review. *BMJ open*, *8*(8), e022202.
31. Naylor, M. D., Hirschman, K. B., Toles, M. P., Jarrín, O. F., Shaid, E., & Pauly, M. V. (2018). Adaptations of the evidence-based transitional care model in the US. *Social Science & Medicine*, *213*, 28-36.
32. Ormond, K. E., Laurino, M. Y., Barlow-Stewart, K., Wessels, T. M., Macaulay, S., Austin, J., & Middleton, A. (2018, March). Genetic counseling globally: Where are we now?. In *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* (Vol. 178, No. 1, pp. 98-107).
33. Ory, M. G., Adepoju, O. E., Ramos, K. S., Silva, P. S., & Vollmer Dahlke, D. (2023). Health equity innovation in precision medicine: Current challenges and future directions. *Frontiers in Public Health*, *11*, 1119736.
34. Papastergiou, J., Quilty, L. C., Li, W., Thiruchselvam, T., Jain, E., Gove, P., ... & Pojskic, N. (2021). Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. *Clinical and Translational Science*, *14*(4), 1359-1368.
35. Pedrosa, A. R. C., Ferreira, Ó. R., & Baixinho, C. R. S. L. (2022). Transitional rehabilitation care and patient care continuity as an advanced nursing practice. *Revista brasileira de enfermagem*, *75*(05), e20210399.
36. Prusaczyk, B., Kripalani, S., & Dhand, A. (2019). Networks of hospital discharge planning teams and readmissions. *Journal of interprofessional care*, *33*(1), 85-92.
37. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in the clinic. *Nature*, *526*(7573), 343-350.
38. Rochon, P. A., & Schmader, K. E. (2019). Drug prescribing for older adults. *Toronto: UpToDate*.
39. Roh, C. Y., Moon, M. J., Yang, S. B., & Jung, K. (2016). Linking emotional labor, public service motivation, and job satisfaction: Social workers in

health care settings. *Social work in public health*, *31*(2), 43-57.

40. Schaaf, C. P., Betancur, C., Yuen, R. K., Parr, J. R., Skuse, D. H., Gallagher, L., ... & Vorstman, J. A. (2020). A framework for an evidence-based gene list relevant to autism spectrum disorder. *Nature Reviews Genetics*, *21*(6), 367-376.
41. Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., ... & Martin, J. H. (2015). Reducing inappropriate polypharmacy: the process of deprescribing. *JAMA internal medicine*, *175*(5), 827-834.
42. Sittig, D. F., & Singh, H. (2010). A new sociotechnical model for studying health information technology in complex adaptive healthcare systems. *BMJ Quality & Safety*, *19*(Suppl 3), i68-i74.
43. Spaulding, E. M., Marvel, F. A., Jacob, E., Rahman, A., Hansen, B. R., Hanyok, L. A., ... & Han, H. R. (2021). Interprofessional education and collaboration among healthcare students and professionals: a systematic review and call for action. *Journal of interprofessional care*, *35*(4), 612-621.
44. Stuijt, C. C. M., Bekker, C. L., Van den Bemt, B. J. F., & Karapinar, F. (2021). Effect of medication reconciliation on patient reported potential adverse events after hospital discharge. *Research in Social and Administrative Pharmacy*, *17*(8), 1426-1432.
45. Tafe, L. J., Gorlov, I. P., De Abreu, F. B., Lefferts, J. A., Liu, X., Pettus, J. R., ... & Chamberlin, M. D. (2015). Implementation of a molecular tumor board: the impact on treatment decisions for 35 patients evaluated at Dartmouth-Hitchcock Medical Center. *The oncologist*, *20*(9), 1011-1018.
46. Tsilimingras, D., Ghosh, S., Duke, A., Zhang, L., Carretta, H., & Schnipper, J. (2017). The association of post-discharge adverse events with timely follow-up visits after hospital discharge. *PloS one*, *12*(8), e0182669.
47. Weeda, E., Gilbert, R. E., Kolo, S. J., Haney, J. S., Hazard, L. T., Taber, D. J., & Axon, R. N. (2023). Impact of pharmacist-driven transitions of care interventions on post-hospital outcomes among patients with coronary artery disease: a systematic review. *Journal of pharmacy practice*, *36*(3), 668-678.
48. Weir, D. L., Motulsky, A., Abrahamowicz, M., Lee, T. C., Morgan, S., Buckeridge, D. L., & Tamblyn, R. (2020). Failure to follow medication changes made at hospital discharge is associated with adverse events in 30 days. *Health services research*, *55*(4), 512-523.
49. Weller, J., Boyd, M., & Cumin, D. (2014). Teams, tribes and patient safety: overcoming barriers to effective teamwork in healthcare. *Postgraduate medical journal*, *90*(1061), 149-154.
50. World Health Organization. (2017, August). *Framework for action on interprofessional education and collaborative practice. 2010*.

Zafar, S. Y., & Peppercorn, J. M. (2017). Patient financial assistance programs: a path to affordability or a barrier to accessible cancer care?. *Journal of Clinical Oncology*, *35*(19), 2113.